In a significant stride forward for biotechnology and healthcare, Vgenomics announces the successful closure of their seed investment round, led by O2 Angel Network and Mumbai Angels. The round also drew enthusiastic participation from prominent Angel investors like Rohit Chanana, Sabine Kapasi, among others.
Vgenomics is utilizing next-generation sequencing technologies to develop diagnostics and therapeutics for rare diseases that affect children; these are diseases that are present at birth and are often caused by alterations in the DNA. Leveraging genomics and artificial intelligence they are bringing novel solutions to market for 175 M+ children suffering from rare diseases across the world.
A team of distinguished women scientists, with a cumulative experience of over 35 years founded Vgenomics in 2022. The team is united by a mission: to pioneer innovative solutions for rare diseases and transform the lives of children globally.
These conditions, though rare individually, are prevalent, particularly in India with an estimated 100 million patients as per IORD (Indian Organization for Rare Diseases).
Rare diseases take an average of 7 years to diagnose, while development of treatments takes 10 to 15 years. Vgenomics is building proprietary tools that will bring diagnostic and therapeutic solutions for multiple rare diseases, decreasing the time of diagnosis and therapeutics development by 80%.
Vgenomics generates revenue from customers that include renowned researchers and clinicians from AIIMS, PGIMER, Dr. Shroff etc. They have received accolades from industry partners, including the prestigious Illumina Grant.
Mr. Rajesh Ranjan, Founder of O2 Angels shared his thoughts.
It rarely happens that we confirm our commitment to a deal in less than 2 hours and Vgenomics is one such deal. Thanks to Dr. Sabine’s walk through and Dr Rahila’s clarity of thoughts on what Vgenomics wish to do. We are very enthused with what Dr Rahila, Dr.
Preeti and team are attempting to do in rare diseases using AI.
O2 Angels is happy to be part of Vgenonics growth journey and wish them the very best and as a deeptech focussed network always looking to support path breaking ideas. Reach us on rajesh@o2angels.net
“Vgenomics’ groundbreaking approach to harnessing next-generation, AI – powered sequencing technologies to address rare diseases is commendable. This investment not only validates their innovative strategy but also propels the journey towards impacting the lives of millions of children affected by rare diseases worldwide.” – Ms. Nandini Mansinghka, CEO of Mumbai Angels on Vgenomics.
“This marks a pivotal advancement in our journey, underscoring the necessity of a scientific strategy tailored for rare diseases. This will help us in uniting organizations dedicated to rare diseases, and establish Vgenomics as the one-stop hub for rare disease solutions” – Rahila Sardar, Founder and CEO, Vgenomics.
“We express our sincere gratitude to our investors for their confidence in Vgenomics. This investment validates our approach and will help us focus on using the next-generation sequencing technologies and machine learning, to develop diagnostics and drugs for rare diseases specific for the Indian population.” – Preeti Gupta Lal, Co-Founder and CSO at Vgenomics said on the fundraising.
The company plans to utilise the investment for building diagnostics solutions and scaling the existing business with neonatologists, gynaecologists, paediatricians, and clinical geneticists.
This infusion of capital not only endorses their groundbreaking approach but also sets the stage for accelerated development and deployment of their solutions, targeting a staggering 175 million children worldwide afflicted with rare diseases.
